Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): A phase 3, double-blind, randomised, placebo-controlled trial

Tools

Vermeire, Séverine, Schreiber, Stefan, Rubin, David T., D'Haens, Geert, Reinisch, Walter, Watanabe, Mamoru, Mehta, Rajiv, Roblin, Xavier, Beales, Ian, Gietka, Piotr, Hibi, Toshifumi, Hospodarskyy, Ihor, Ritter, Timothy, Genovese, Mark C., Kwon, Paul, Santermans, Eva, Le Brun, Franck-Olivier, Barron, Rahul, Masior, Tomasz and Danese, Silvio (2025) Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): A phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology & Hepatology, 10 (2). pp. 138-153. ISSN 2468-1253

[thumbnail of Vermeire_etal_2025_LancetGH]

Preview

PDF (Vermeire_etal_2025_LancetGH) - Published Version
Available under License Creative Commons Attribution.
Download (764kB) | Preview

Abstract

There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's disease.

Item Type:	Article
Additional Information:	Acknowledgments: The DIVERSITY study was sponsored by Galapagos (Mechelen, Belgium) and Gilead Sciences (Foster City, CA, USA) was a collaborator for the study.
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.scopus.com/inward/record.url?... https://linkinghub.elsevier.com/retrieve...
Depositing User:	LivePure Connector
Date Deposited:	04 Dec 2024 01:43
Last Modified:	27 Feb 2025 01:16
URI:	https://ueaeprints.uea.ac.uk/id/eprint/97894
DOI:	10.1016/S2468-1253(24)00272-3

Downloads

Downloads per month over past year

Actions (login required)

View Item